Typenex Medical Logo
Toll Free: 866.897.3639
PIFA Heparin

PIFA Heparin/PF4™

Heparin Induced Thrombocytopenia (HIT) is a life-and-limb threatening potential complication of Heparin therapy. An immune-mediated condition where antibodies to complexes of Heparin/Platelet Factor 4 (PF4) play a major role in the pathogenesis, HIT is often seen in patients on Heparin post cardiac or orthopedic surgery.

Rule out tests such as PIFA Heparin/PF4™ are rapidly becoming a standard of care. PIFA Heparin/PF4™ is a simple, cost-effective immunoassay for the qualitative detection of antibodies to PF4-sensitized microspheres.

Information about PIFA Heparin/PF4™

Ruling out PF4 antibodies rapidly enables clinicians to avoid unnecessary heparin discontinuation and use of alternative anticoagulant therapies, such as Direct Thrombin Inhibitors (DTIs) that can result in:

  • Clinical monitoring requirements and associated costs
  • Increased length of stay (LOS)
  • Potential side effects
  • High drug therapy costs

Key Benefits of PIFA Heparin/PF4™

Ideal for labs of all sizes, PIFA Heparin/PF4™ offers several advantages:

  • Rule out Heparin/PF4 antibodies that are associated with HIT
  • Rapid results (<1 hour)
  • Dramatic cost savings potential

Resources

Ordering Information

PIFA Heparin/PF4™ (serum) Devices (6 tests/pack) 4036025
PIFA Heparin/PF4™ (serum) – Controls, 6 Panel (5 Pos/1 Neg) 4036028
PIFA Heparin/PF4™ (serum) – Controls, 2 Panel (1 Pos/1 Neg) 4036027
Request a sample

Typenex Medical is a proud distributor of PIFA Heparin/PF4™.

PIFA Heparin/PF4™ is a trademark of Akers Biosciences, Inc.